GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
The key to the #commercialization journey is actually in developing relationships with stakeholders through an understanding of priorities, rather than trying to be an expert in all areas. #regenmed #commercialization @MTPConnect_AUS
It was useful to catch up with @BlueRockTx, @CGTCatapult and @CCRM_ca at the @ISSCR meeting in Toronto today. Three important participants in the iPSC #Quality Round 2019.
Fate Tx opens new GMP facility for iPSC therapeutic development
Fate Therapeutics Announces the Opening of its cGMP Manufacturing Facility Dedicated to iPSC-derived Cell Therapies | Fate Therapeutics, Inc.
The Investor Relations website contains information about Fate Therapeutics, Inc.'s business for stockholders, potential investors, and financial anal...
At the MARS Centre at the University of Toronto today, visiting @CCRM and holding discussions with other Canadian Participants of the iPSC Quality Round 2019 today and tomorrow.
Congrats @StemCellNetwork for another successful TMM. As always, it is wonderful to work with you on the meeting. Thanks to all speakers and attendees. See you next year!
Stem Cell Network on Twitter
“#TMM2019 has officially concluded! Thank you to our co-host @CCRM_ca and to all our generous sponsors!!! We hope to see you all in Vancouver fo...
Regulated, Reputable & Reliable how #stemcell treatments should be developed with proper regulatory oversight around the world #TMM2019 @StemCellNetwork nice overview from Health Canada
Thanks to CellCAN for a useful workshop on iPSC quality and standardization at Till McCulloch 2019 Meeting in Montréal today.
GAiT Director & CCRM CEO Michael May opens the Till McCulloch Meeting 2019 in Montréal